

Financial Results for the Fiscal Year Ended March 31, 2024

 **DAIKEN MEDICAL CO., LTD.**

Tokyo Stock Exchange Standard Market
Securities Code: 7775



☐ Table of Contents

**Summary of Financial Results for
the Fiscal Year Ended March 31, 2024**

**Forecast for the Fiscal Year Ending
March 31, 2024**

Strategy for Growth

Summary of Financial Results for the Fiscal Year Ended March 31, 2024

Financial Results

(Unit: million yen)

	Fiscal year ended March 31, 2023	Fiscal year ended March 31, 2024	YoY
Net sales	9,137	9,750	+6.7%
Gross profit (Gross margin)	3,530 (38.6%)	3,981 (40.8%)	+12.8%
SG&A expenses (SG&A ratio)	2,475 (27.1%)	2,539 (26.0%)	+2.6%
Operating profit	1,054	1,442	+36.8%
Ordinary profit (Ordinary profit ratio)	1,053 (11.5%)	1,450 (14.9%)	+37.6%
Profit	712	988	+38.8%
Dividend per share	¥20.0	¥21.0	—


Sales by Segment (Year-on-Year Comparison)

Steady sales of mainstay products
and expansion of AMY adoption

(Unit: million yen)

	Fiscal year ended March 31, 2023		Fiscal year ended March 31, 2024		YoY
	Total	Component ratio	Total	Component ratio	
Suction device	5,820	63.7%	6,190	63.5%	+6.4%
(QinPot)	(2,303)	(25.2%)	(2,489)	(25.5%)	(+8.1%)
(FitFix+BYRON)	(3,517)	(38.5%)	(3,701)	(38.0%)	(+5.2%)
Infusion pump	2,008	22.0%	2,104	21.6%	+4.8%
(PCA Set+AMY)	(1,725)	(18.9%)	(1,826)	(18.7%)	(+5.9%)
Electric Power Operated Pump	248	2.7%	262	2.7%	+5.5%
Hand Washing Equipment	585	6.4%	678	7.0%	+16.0%
Other	473	5.2%	513	5.2%	+8.3%
Total	9,137	100.0%	9,750	100.0%	+6.7%

Analysis of Variance of Ordinary Profit for the Fiscal Year Ended March 2024 (YoY)



Forecast for the Fiscal Year Ending March 31, 2025


□ Forecasts and Dividends for the Fiscal Year Ending March 31, 2025

(Unit: million yen)

	Fiscal year ended March 31, 2024 (Actual)	Fiscal year ending March 31, 2025 (Forecast)	YoY
Net sales	9,750	10,100	+3.6%
Operating profit	1,442	1,500	+4.0%
Ordinary profit (Ordinary profit ratio)	1,450 (14.9%)	1,500 (14.9%)	+3.4%
Profit	988	1,030	+4.2%
Dividend per share	¥21.0	¥22.0	—
Dividend payout ratio	61.0%	61.4%	—

Financial Results

(Unit: million yen)



Strategy for Growth

Mid-to-long Term Strategy Overview (4 Growth Pillars)

1. Replacement of existing products

**2. Product development and launch
complementing existing businesses**

3. Dominating the overseas market with AMY

4. Market introduction for new fields and markets

Mid-to-long Term Strategy Overview and Growth Strategy

Business restructuring
(Source of profit
for growth investment)

Replacement of existing products

**Improved
BYRON**

Patent number 7269851, etc.

Market trials underway at multiple medical institutions



FitFix



Syrinjector



Balloonjector



Patents expired

AMY

Patent number 6726166, etc.

Expanding sales and profits for acute phase and home care applications

amy pcn
カデック イミー-PCA



Controller



Built-in micropump

Mid-to-long Term Strategy Overview and Growth Strategy

Business restructuring
(Source of profit
for growth investment)

Product development and launch
complementing existing businesses

Suction device
business

Infusion pump
business

Electric Power
Operated
Pump business

Other

AMY

Deployment for chemotherapy

(Anticancer drug administration)


Development of derivative products
from existing businesses

Mid-to-long Term Strategy Overview and Growth Strategy

Sales expansion in overseas markets

Entering the overseas market with AMY

Also sell highly original products on overseas markets



State of progress

Acquisition of MDR
Planned for **FY2024**

* Acquisition expected in early summer at earliest

Completed building organization for

clinical evaluation

to be conducted in Europe after acquisition
(Awaiting MDR acquisition)

Development of new fields and products


Launching major products in new fields and markets

Expansion into multiple domains
through the application of fundamental micro-pump technology


Existing areas

Internal medicine fields

**Insulin pump
(Diabetes treatment)**



Domestic market scale
Over ¥30.0 billion





Product development research center (Izumi-shi, Osaka, Japan)

 **DAIKEN MEDICAL CO., LTD.**

For inquiries regarding this material and information on IR, please contact the below.

DAIKEN MEDICAL CO.,LTD.

Finance & Accounting Department

TEL: 06-6231-9917

URL: <https://www.daiken-iki.co.jp/ir> (in Japanese)

Any forward-looking statements in this document, including figures and strategies, are based on current assumptions and projections in light of the information currently available to us and are subject to risks and uncertainties. Actual results may differ from the forecasts due to various factors.